Exchange Capital Management Inc. Sells 1,797 Shares of Kenvue Inc. (NYSE:KVUE)

Exchange Capital Management Inc. cut its holdings in Kenvue Inc. (NYSE:KVUE) by 0.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 192,770 shares of the company’s stock after selling 1,797 shares during the quarter. Exchange Capital Management Inc.’s holdings in Kenvue were worth $4,116,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC boosted its position in shares of Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after purchasing an additional 3,075,019 shares in the last quarter. State Street Corp increased its stake in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after buying an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after buying an additional 7,115,374 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Kenvue by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock worth $1,029,810,000 after purchasing an additional 399,846 shares during the last quarter. Finally, Harris Associates L P increased its stake in shares of Kenvue by 7.5% during the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock worth $727,658,000 after purchasing an additional 2,186,114 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $23.33 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $44.72 billion, a price-to-earnings ratio of 44.01, a PEG ratio of 2.62 and a beta of 1.45. The stock has a 50 day moving average of $21.33 and a 200 day moving average of $22.21. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Analyst Ratings Changes

KVUE has been the topic of several recent analyst reports. Barclays lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Piper Sandler boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday. UBS Group lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.